Rebecca B. Robertson
Known title: DirectorCIK: 0001201585
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Transaction History
| CBLL | ▲ Buy | Grant | 7,838 | $0 | 6/2/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 8,759 | $0 | 5/21/2026 | View on chart |
| CBLL | ▼ Sell | Open Market | 827 | $15K | 3/3/2026 | View on chart |
| CBLL | ▼ Sell | Open Market | 2,500 | $55K | 1/2/2026 | View on chart |
| CBLL | ▲ Buy | Option Exercise | 2,500 | $6K | 1/2/2026 | View on chart |
| CBLL | ▲ Buy | Option Exercise | 5,000 | $11K | 12/8/2025 | View on chart |
| CBLL | ▼ Sell | Open Market | 5,000 | $100K | 12/8/2025 | View on chart |
| CBLL | ▼ Sell | Open Market | 827 | $14K | 12/2/2025 | View on chart |
| CBLL | ▼ Sell | Open Market | 827 | $9K | 9/3/2025 | View on chart |
| CBLL | ▼ Sell | Open Market | 11,188 | $200K | 6/18/2025 | View on chart |
| CBLL | ▼ Sell | Open Market | 7,445 | $131K | 6/17/2025 | View on chart |
| CBLL | ▲ Buy | Option Exercise | 545 | $1K | 6/16/2025 | View on chart |
| CBLL | ▼ Sell | Open Market | 20,000 | $343K | 6/16/2025 | View on chart |
| CBLL | ▲ Buy | Option Exercise | 19,455 | $71K | 6/16/2025 | View on chart |
| CBLL | ▲ Buy | Grant | 8,828 | $0 | 6/10/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,387 | $91K | 5/22/2025 | View on chart |
| CBLL | ▲ Buy | Grant | 6,618 | $0 | 10/11/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,434 | $229K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,757 | $0 | 5/25/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,205 | $0 | 5/18/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,500 | $51K | 5/2/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 533 | $51K | 5/2/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 967 | $94K | 5/2/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 533 | $63K | 2/1/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,500 | $51K | 2/1/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 300 | $35K | 2/1/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 667 | $79K | 2/1/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 278 | $38K | 11/1/2021 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,108 | $38K | 11/1/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 1,222 | $166K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CeriBell Gets FDA Clearance for New EEG Analysis Tools
CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.
CeriBell Gets FDA Clearance for New EEG Analysis Tools. CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.